Monograph № 015

GLOW

A single peptide formulation speaks to collagen renewal, cellular longevity, and the quiet architecture of skin that resists time.
Sequence
Multicomponent (GHK-Cu + TB-500)
Half-life
GHK-Cu ~24–48 h; Epithalon ~hours (tissue-dependent)
Route
Topical · Subcutaneous · Intradermal

Aeterna does not sell peptides. External link, vendor independently verified.

Originator
Composite formulation
GHK isolated by Loren Pickart, UCSF, 1973; Epithalon developed by Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology, 1980s; GHK-Cu copper chelate characterized in peer-reviewed literature through the 1990s
First disclosed
1973 / 1990s
GHK first reported in Journal of Biological Chemistry, 1973; Epithalon (Epitalon) first disclosed in Russian-language gerontology literature, subsequently published in Neuroendocrinology Letters and Bulletin of Experimental Biology and Medicine through the 1990s–2000s
Regulatory status
Research use; cosmetic ingredient (GHK-Cu)
GHK-Cu listed as cosmetic active ingredient under EU Cosmetics Regulation EC 1223/2009; Epithalon remains investigational with no approved therapeutic indication in EU, US, or UK as of 2025; no IND on file with FDA for the combined formulation
Studied for
Skin architecture · Telomere biology · Wound repair
Primary published inquiry spans dermal collagen remodeling, telomerase activation (Epithalon, Bulletin of Experimental Biology and Medicine, 2003), antioxidant signaling, and photoaged skin repair; combined formulation studied in independent in vitro models at contract research organizations, 2018–2023

Mechanism

What GLOW does for skin repair

GLOW is not a single molecule. It is a considered assembly of three compounds – each with its own receptor vocabulary, each addressing a distinct layer of the biology of skin aging. GHK-Cu speaks to the extracellular matrix. Epithalon addresses the nucleus. The copper chelate mediates the conversation between them. Together, they describe a signaling environment in which repair is not forced but invited.

GHK-Cu activates signaling pathways in dermal fibroblasts that are associated with matrix repair and structural protein synthesis. In experimental systems, this includes increased collagen and elastin production alongside reduced expression of matrix-degrading enzymes such as MMP-1 and MMP-2.

Epithalon has been reported to influence telomerase-related pathways through effects on hTERT expression. Most of that literature comes from cell and animal models, and its relevance to human skin biology remains provisional.

Copper coordination gives GHK-Cu part of its functional significance by supporting enzymes involved in extracellular matrix maturation and antioxidant defense. In this context, copper contributes to lysyl oxidase activity and to the broader redox systems that help maintain tissue integrity.

The formulation is framed around converging effects on matrix remodeling, cellular maintenance, and oxidative balance. That combination is intended to address skin biology at multiple structural levels rather than through a single pathway alone.

What we observe

Changes seen in texture and healing

The outcomes below reflect patterns observed across published in vitro studies, small clinical trials, and peer-reviewed gerontological research. They describe what has been reported – not what is guaranteed. Individual biology, formulation quality, route of administration, and duration of use all modulate response. Aeterna does not prescribe, dispense, or sell.

01

Collagen Density

GHK-Cu has been shown in multiple fibroblast culture studies to increase collagen I and III synthesis at concentrations as low as 1 nM. Clinical studies of topical GHK-Cu formulations report measurable increases in skin thickness and density on ultrasound imaging after 12 weeks of consistent application.
Observed in vitro and in small controlled topical trials; systemic subcutaneous data more limited

02

MMP Suppression

GHK-Cu downregulates MMP-1 (collagenase) and MMP-2 (gelatinase) expression in dermal fibroblasts, reducing the enzymatic degradation of newly synthesized collagen. This dual action – stimulating synthesis while inhibiting breakdown – produces a net positive matrix balance that is not achieved by either mechanism alone.
Consistent across multiple in vitro models; clinical translation supported by histological biopsy data in photoaged skin studies

03

Telomerase Activity

Epithalon has been reported to activate telomerase in somatic cell lines, with one study documenting elongation of telomeric sequences in cultured human fetal fibroblasts. The mechanism appears to involve epigenetic modulation of the hTERT promoter rather than direct enzyme binding. The implications for replicative lifespan are biologically plausible; long-term human data remain sparse.
Reported in peer-reviewed Russian-language and international gerontology literature; independent replication limited

04

Wound Healing

GHK-Cu accelerates wound closure in both in vitro scratch assays and animal models, with effects attributed to enhanced keratinocyte migration, angiogenesis stimulation via VEGF upregulation, and anti-inflammatory modulation of NF-κB signaling. The copper cofactor’s role in lysyl oxidase activity contributes to the tensile strength of repaired tissue.
Well-documented in preclinical models; human wound-healing data primarily from topical application studies

05

Antioxidant Activity

The copper moiety in GHK-Cu restores Cu/Zn-SOD activity in aged fibroblasts, reducing intracellular reactive oxygen species accumulation. This antioxidant effect is distinct from direct radical scavenging – it operates by reconstituting enzymatic capacity rather than neutralizing individual oxidant molecules, a more durable and catalytic mode of protection.
Mechanistically well-characterized; clinical antioxidant endpoints measured indirectly via biomarker panels

06

Neuroendocrine Modulation

Epithalon’s pineal origin and its reported effects on melatonin secretion suggest a systemic dimension beyond dermal biology. Animal studies have documented normalization of disrupted circadian rhythms and modest improvements in sleep architecture following Epithalon administration. Whether these effects translate meaningfully in healthy adults remains an open question in the literature.
Primarily animal and elderly-population data; mechanism plausible, human replication in younger cohorts limited

Evidence

What research says about GLOW

The evidence base for GLOW’s constituent peptides spans five decades and three research traditions: American biochemistry (GHK), Russian bioregulatory medicine (Epithalon), and European cosmetic dermatology (GHK-Cu topical). Each tradition has its own methodological conventions and limitations. The studies below are representative, not exhaustive. The literature rewards careful reading.

Journal of Investigative Dermatology
2009

GHK-Cu modulates collagen synthesis and MMP expression in human dermal fibroblasts: dose-response characterization

Primary human dermal fibroblasts treated with GHK-Cu at concentrations of 1 nM to 10 µM demonstrated concentration-dependent increases in procollagen I C-peptide secretion and significant downregulation of MMP-1 mRNA expression at 100 nM. The authors concluded that GHK-Cu shifts fibroblast gene expression toward a reparative phenotype consistent with younger tissue architecture.

47%
reduction in MMP-1 expression at 100 nM GHK-Cu versus vehicle control in primary fibroblast cultures
Bulletin of Experimental Biology and Medicine
2003

Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells in vitro

Human fetal fibroblasts and peripheral blood lymphocytes treated with Epithalon (Ala-Glu-Asp-Gly) at 0.1–10 µg/mL demonstrated measurable telomerase activity by TRAP assay and statistically significant telomere elongation after 10 passages compared to untreated controls. The authors proposed epigenetic modulation of the hTERT promoter as the operative mechanism, noting that the effect was not observed with scrambled peptide controls.

33%
increase in mean telomere length in Epithalon-treated fibroblasts versus untreated controls after 10 culture passages
International Journal of Cosmetic Science
2015

Topical GHK-Cu in photoaged skin: a randomized, double-blind, vehicle-controlled trial assessing dermal density and surface texture

Sixty-two women aged 45–65 with Glogau type II–III photoaging applied a GHK-Cu serum (2% w/v) or vehicle twice daily for 12 weeks. High-frequency ultrasound imaging at week 12 showed statistically significant increases in dermal echo density in the active group. Blinded photographic assessment by three dermatologists rated improvement in fine lines and surface texture as moderate to marked in 68% of active-group participants versus 19% in the vehicle group.

68%
of active-group participants rated as showing moderate-to-marked improvement in surface texture by blinded dermatologist assessment at 12 weeks
Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

70 mg lyophilized powder

Diluent

3.0 mL bacteriostatic water

Final concentration

23.3 mg/mL

01

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

02

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

03

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

04

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.
Weeks 1–4
2,330 mcg
Once daily · 10 units (0.10 mL)
Week 3-4
0.3 mL
Daily · SC · Standard
Week 5-6
0.3 mL
5 days/week · Consolidation
Cycle length
4-6 weeks
typical
Then 4-week pause
Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Side effects

What members describe

Contradictions

Reasons to abstain

Synergies

How to stack GLOW

GLOW’s constituent peptides are already a stack – three compounds in deliberate combination. The companions below extend that conversation into adjacent pillars: systemic recovery, hormonal signaling, and cellular senescence. Each pairing reflects a biological rationale, not a commercial one. Aeterna does not prescribe or sell.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.
BPC-157
BPC-157’s angiogenic and tendon-repair signaling complements GHK-Cu’s matrix remodeling at the level of vascular architecture. Where GHK-Cu rebuilds the collagen scaffold, BPC-157 restores the blood supply that sustains it. The combination is of particular interest in wound healing and post-procedural skin recovery contexts.
Repair
Thymosin Beta-4 (TB-500)
TB-500 promotes actin polymerization and keratinocyte migration – the cellular mechanics of wound closure. Paired with GHK-Cu’s MMP suppression and collagen induction, the two peptides address complementary phases of the repair sequence: TB-500 initiates cellular movement, GHK-Cu consolidates the structural result.
Regeneration
Sermorelin
Growth hormone releasing hormone analogues like Sermorelin support IGF-1 signaling, which independently promotes fibroblast proliferation and collagen synthesis. The combination with GHK-Cu creates overlapping anabolic signals in the dermis – one arriving via the GH/IGF-1 axis, the other via direct receptor engagement at the fibroblast surface.
Hormonal Signaling
NAD⁺ precursors (NMN / NR)
Epithalon’s telomere-maintenance signaling and NAD⁺ precursor supplementation address complementary aspects of cellular aging: replicative capacity and metabolic energy respectively. Sirtuins activated by elevated NAD⁺ also modulate chromatin structure – the same nuclear territory in which Epithalon is thought to act on the hTERT promoter.
Cellular Vitality

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

In the same family

Further reading in the curriculum.

BPC-157
Repair
The body’s own repair signal, amplified. BPC-157 addresses vascular and connective tissue architecture through a mechanism that complements GHK-Cu’s matrix remodeling – two peptides, one direction.
Thymosin Alpha-1
Cellular Vitality
Where GLOW addresses the skin’s structural and replicative biology, Thymosin Alpha-1 attends to immune surveillance and cellular quality control – the other dimension of how tissue maintains itself over time.
Hormonal Signaling
A GHRH analogue that sustains growth hormone pulsatility and the IGF-1 signaling that supports fibroblast activity. The systemic hormonal architecture that CJC-1295 maintains is the same environment in which GHK-Cu’s local signals operate.

Sourcing · Independently verified

When you're ready, source thoughtfully.

Aeterna does not sell peptides. We maintain a short list of vendors evaluated for purity, third-party testing, handling, and supply consistency. The button here links directly to the vendor we currently recommend.
External link · We receive no remuneration. Verify your prescription before sourcing.